0001193125-24-068566.txt : 20240315 0001193125-24-068566.hdr.sgml : 20240315 20240315070031 ACCESSION NUMBER: 0001193125-24-068566 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240311 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240315 DATE AS OF CHANGE: 20240315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 134196017 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24752437 BUSINESS ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d787456d8k.htm 8-K 8-K
AILERON THERAPEUTICS INC NASDAQ false 0001420565 0001420565 2024-03-11 2024-03-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 11, 2024

 

 

Aileron Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38130   13-4196017

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

738 Main Street #398

Waltham, MA

   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 995-0900

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ALRN   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Manuel C. Alves-Aivado Ceases to Serve as Chief Executive Officer

On March 11, 2024, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), and Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024 (the “Separation Date”). Dr. Aivado will remain a member of the Company’s Board of Directors (the “Board”). Dr. Aivado’s resignation from the Company was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

As a non-employee director, following the Separation Date, Dr. Aivado will be compensated in accordance with the terms of the Company’s non-employee director compensation program as described in the Company’s definitive proxy statement for the Company’s 2023 annual meeting of stockholders, filed with the SEC on January 29, 2024.

Election of Brian Windsor as Chief Executive Officer and Director

On March 11, 2024, the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024. In connection with his election as Chief Executive Officer of the Company, Dr. Windsor will serve as the Company’s principal executive officer. Dr. Windsor will continue to serve as President of the Company. Dr. Windsor will serve as a Class I director with a term expiring at the 2024 annual meeting of stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal.

Dr. Windsor, age 58, has served as the Company’s President and Chief Operating Officer since October 2023. Prior to becoming President and Chief Operating Officer, Dr. Windsor served, since July 2013, as President, Chief Executive Officer and a director of Lung Therapeutics, Inc. (“Lung”), until its acquisition by the Company in October 2023. From September 2019 to March 2022, Dr. Windsor served as a director and the Chief Science Officer of TFF Pharmaceuticals, Inc., a public biopharmaceutical company that Lung spun out into an independent company. From January 2018 to March 2022, Dr. Windsor provided consulting services to TFF Pharmaceuticals, Inc. in the areas of science and technology. From November 2009 to March 2013, Dr. Windsor served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies, Inc., an early stage technology venture creation and management company, where he served as Managing Director or President for portfolio companies. Dr. Windsor holds a B.S. and a Ph.D. in molecular biology from The University of Texas at Austin.

There is no arrangement or understanding between Dr. Windsor and any other person pursuant to which he was elected as an officer or director of the Company. Dr. Windsor has no family relationship with any of the executive officers or directors of the Company. There are no transactions and no proposed transactions between Dr. Windsor and the Company that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Severance Agreement with Manuel C. Alves Aivado

In connection with Dr. Aivado’s separation from the Company, and in accordance with the Severance Agreement, dated as of September 6, 2018, between the Company and Dr. Aivado (the “Severance Agreement”), Dr. Aivado is entitled to receive his base salary for eighteen (18) months following the Separation Date, payments on Dr. Aivado’s behalf of the monthly premiums for medical insurance coverage under COBRA until the earlier of the date that is eighteen (18) months following the Separation Date or the date on which Dr. Aivado becomes eligible to receive group health insurance coverage through another employer, a lump sum payment equal to one and one-half times Dr. Aivado’s target bonus for the 2024 calendar year, and acceleration in full of the vesting of any unvested equity awards. Dr. Aivado’s receipt of these post-separation benefits under the Severance Agreement is conditioned upon his execution of a severance and release of claims agreement with the Company.

Item 7.01

Regulation FD Disclosure

On March 12, 2024, the Company issued a press release announcing the executive leadership transitions. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.    Description
99.1    Press Release issued by the Company on March 12, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AILERON THERAPEUTICS, INC.
Date: March 15, 2024     By:  

/s/ Brian Windsor, Ph.D.

      Brian Windsor, Ph.D.
      President and Chief Executive Officer
 EX-99.1 2 d787456dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Aileron Therapeutics Announces CEO Transition

Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer

Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class

medicines for orphan pulmonary and fibrosis diseases

WALTHAM, Mass., Mar. 12, 2024 (GLOBE NEWSWIRE) – Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024. Dr. Windsor succeeds Manuel Aivado, M.D., Ph.D., who has stepped down as CEO and will continue to serve on the Company’s Board of Directors. The transition follows the Company’s acquisition of Lung Therapeutics, Inc. (“Lung”) in October of last year.

“It has been a privilege to lead Aileron and I am proud to have worked alongside so many dedicated and passionate colleagues committed to transforming patient’s lives,” said Dr. Aivado. “I am excited to continue my journey with Aileron as a member of the Board and to support the Company through its next chapter under Brian’s capable leadership.”

Dr. Windsor has previously served as President and Chief Operating Officer of Aileron since October 2023. Prior to Aileron, he served as President, CEO and director of Lung. He has also served as Chief Science Officer and Director of TFF Pharmaceuticals, Inc., a public biopharmaceutical company that Lung spun out into an independent company, for which Dr. Windsor had previously provided consulting services in the areas of science and technology. Before his position at Lung, he served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company, where he oversaw all aspects of the company’s pharmaceutical drug development. Before joining Enavail, he directed portfolio company management for Emergent Technologies, Inc., an early-stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. Dr. Windsor holds a B.S. and a Ph.D. in Molecular Biology, both from The University of Texas at Austin.

“I am honored to assume the role of CEO of Aileron, and am encouraged for its promising future,” said Dr. Windsor. “Following our strategic prioritization of the development of LTI-03 and LTI-01, we look forward to advancing our pipeline of novel therapies for life-threatening pulmonary conditions.”

Dr. Windsor continued, “I would like to sincerely thank Dr. Aivado for his many contributions to Aileron. We are delighted that we will continue to benefit from his expertise and experience as a member of the Board of Directors as we navigate our next phase of development and beyond.”

About Aileron Therapeutics

Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron’s lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron’s second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.

Forward-Looking Statements

This press release may contain forward-looking statements of Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the timing and expectation of the results of the Phase 1b study of LTI-03; future expectations, plans and prospects for the Company following the merger transaction between the Company and Lung Therapeutics, Inc. that closed in the fourth quarter of 2023 (the “Merger”); the use of proceeds from the private placement conducted concurrently with the Merger; the sufficiency of the Company’s cash resources; the benefits of the Merger; certain milestones of the Company; the projected cash runway of the Company; the status and plans for clinical trials, including the timing of data; future product development; and the potential commercial opportunity of LTI-03 and LTI-01. We use words such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “would,” “can,” “could,” “should,” “continue,” and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to the ability to recognize the anticipated benefits of the Merger; the ability to maintain the listing of the common stock of the Company on The Nasdaq Stock Market; changes in applicable laws or regulations; the possibility that the Company may be adversely

affected by other economic, business, and/or competitive factors, including risks inherent in pharmaceutical research and development, such as: adverse results in the Company’s drug discovery, preclinical and clinical development activities; the risk that the results of preclinical studies and early clinical trials may not be replicated in later clinical trials; the Company’s ability to enroll patients in its clinical trials; and the risk that any of its clinical trials may not commence, continue or be completed on time, or at all, decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies with respect to our development candidates; our ability to obtain, maintain and enforce intellectual property rights for our platform and development candidates; our potential dependence on collaboration partners; competition; uncertainties as to the sufficiency of the Company’s cash resources to fund its planned activities for the periods anticipated and the Company’s ability to manage unplanned cash requirements; and general economic and market conditions; as well as the risks and uncertainties discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which is on file with the United States Securities and Exchange Commission (the “SEC”), the risks and uncertainties discussed under the heading “Risk Factors” of the Company’s Current Report on Form 8-K filed with the SEC on January 25, 2024, and in subsequent filings that the Company files with the SEC. These forward-looking statements should not be relied upon as representing the Company’s view as of any date subsequent to the date of this press release, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations & Media Contact:

Argot Partners

aileron@argotpartners.com

212-600-1902

EX-101.SCH 3 alrn-20240311.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 alrn-20240311_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 alrn-20240311_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g787456g0314222626238.jpg GRAPHIC begin 644 g787456g0314222626238.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Mar. 11, 2024
Cover [Abstract]  
Entity Registrant Name AILERON THERAPEUTICS INC
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001420565
Document Type 8-K
Document Period End Date Mar. 11, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-38130
Entity Tax Identification Number 13-4196017
Entity Address, Address Line One 738 Main Street #398
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 995-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALRN
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alrn-20240311.xsd alrn-20240311_lab.xml alrn-20240311_pre.xml d787456d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d787456d8k.htm": { "nsprefix": "alrn", "nsuri": "http://www.aileronrx.com/20240311", "dts": { "schema": { "local": [ "alrn-20240311.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "alrn-20240311_lab.xml" ] }, "presentationLink": { "local": [ "alrn-20240311_pre.xml" ] }, "inline": { "local": [ "d787456d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-03-11_to_2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d787456d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-03-11_to_2024-03-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d787456d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aileronrx.com//20240311/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-068566-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-068566-xbrl.zip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end XML 18 d787456d8k_htm.xml IDEA: XBRL DOCUMENT 0001420565 2024-03-11 2024-03-11 AILERON THERAPEUTICS INC NASDAQ false 0001420565 8-K 2024-03-11 DE 001-38130 13-4196017 738 Main Street #398 Waltham MA 02451 (617) 995-0900 false false false false Common Stock, $0.001 par value per share ALRN false